Home Newsfeeds Goldman Sachs Maintains Sell on YPF, Raises Price Target to $5.8

Goldman Sachs Maintains Sell on YPF, Raises Price Target to $5.8

Goldman Sachs analyst Bruno Amorim maintains YPF (NYSE:YPF) with a Sell and raises the price target from $5.1 to $5.8.

byBenzinga Newsdesk

January 27, 2023

1 minute read

Goldman Sachs analyst Bruno Amorim maintains YPF (NYSE:YPF) with a Sell and raises the price target from $5.1 to $5.8.

Will QLYS’s Strategy Shift Pay Off? Analyst Eyes The Potential Amid Elevated Competitive Risks

By Nabaparna Bhattacharya

August 18, 2:46 PM

Stephens analyst Brian Colley initiated the coverage on Qualys, Inc. (NASDAQ: QLYS) with an

QLYS

Analyst Ratings

What 11 Analyst Ratings Have To Say About Bilibili

By Benzinga Insights

August 18, 3:00 PM

Analysts have provided the following ratings for Bilibili (NASDAQ:BILI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

BILI

RG6501 Phase 1/2a Results To Be Featured At Eyecelerator At 2023 American Academy Of Ophthalmology Annual Meeting

By Benzinga Newsdesk

October 24, 8:16 AM

Company Also Will Present at "Mapping the Future of Geographic Atrophy" Session at Eyecelerator@AAO 2023Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing

LCTX

Analyst Ratings

Analyst Expectations for Colgate-Palmolive’s Future

By Benzinga Insights

October 11, 1:00 PM

Analysts have provided the following ratings for Colgate-Palmolive (NYSE:CL) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

Goldman Sachs Maintains Sell on YPF, Raises Price Target to $5.8

Related Posts

Will QLYS’s Strategy Shift Pay Off? Analyst Eyes The Potential Amid Elevated Competitive Risks

What 11 Analyst Ratings Have To Say About Bilibili

RG6501 Phase 1/2a Results To Be Featured At Eyecelerator At 2023 American Academy Of Ophthalmology Annual Meeting

Analyst Expectations for Colgate-Palmolive’s Future